Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

The purpose of the Connect® MDS/AML Disease Registry is to provide unique insights into treatment regimens and sequencing of these regimens as they relate to clinical outcomes of patients with newly diagnosed MDS, ICUS or AML in routine clinical practice and evaluate molecular and cellular markers that may provide further prognostic classification and/or might be predictive of therapy outcomes.

Key Inclusion Criteria:
• Newly diagnosed primary or secondary MDS, AML or ICUS (must enroll within 60 days of diagnosis)

• AML patients must be at least 55 years old

• MDS/ICUS patients must be at least 18 years old
Cancer, All Other
James Congdon, DO
Celgene Corporation
Virginia Sanchez
  • Providence Regional Cancer Partnership - Everett